NCT02035553View on ClinicalTrials.gov

A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis

PHASE2CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

September 28, 2016

Study Completion Date

October 27, 2016

Conditions
Alzheimer's Disease Psychosis
Interventions
DRUG

Pimavanserin tartrate

Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)

DRUG

Placebo

Placebo, two tablets, once daily by mouth

Trial Locations (1)

Unknown

London

Sponsors
All Listed Sponsors
lead

ACADIA Pharmaceuticals Inc.

INDUSTRY